Kymera Therapeutics, Inc.

Kymera Therapeutics Presents New Preclinical IBD Data for KT-579, a First-in-Class, Oral IRF5 Degrader, at Digestive Disease Week

Kymera Therapeutics Announces First Quarter 2026 Financial Results and Provides a Business Update

Kymera Therapeutics to Report First Quarter 2026 Financial Results on April 30, 2026

Kymera Therapeutics Announces U.S. FDA Fast Track Designation for KT-621, a First-in-Class, Oral STAT6 Degrader for the Treatment of Moderate to Severe Asthma

Kymera Therapeutics Announces Gilead Sciences’ Option Exercise to License KT-200, Oral CDK2 Molecular Glue Degrader Development Candidate